Oncology

Mundipharma Oncology aims to provide new, effective medicines for patients with cancer. Our oncology pipeline includes products for treating neuro-oncological and haematological malignancies. In the near future, a number of new exciting products will lead Mundipharma and its associates to new frontiers to meet the unmet needs of patients with different types of cancer.

In the coming months and years, we will see new additions to the range of products available from Mundipharma Oncology due to new licensing agreements with Novelos Therapeutics and BioCryst Pharmaceuticals.

DepoCyte®

DepoCyte® is a sustained release liposomal cytarabine injection. It is indicated specifically for the treatment of lymphomatous meningitis.

Bendamustine

Bendamustine is a water-soluble, hybrid cytotoxic alkylating agent that is indicated for the treatment of chronic lymphocytic leukaemia (CLL).  Bendamustine is currently licensed in Germany and Switzerland and is undergoing registration in other countries.